Jaguar health provides updates on canalevia (crofelemer), the first plant-based prescription medicine under development for chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs

Canalevia would be first and only fda-approved plant-based medicine for dogs that suffer from diarrhea during chemotherapy canalevia will be available by fourth quarter 2021, if conditionally approved san francisco, ca / accesswire / may 18, 2021 / jaguar health, inc. (nasdaq:jagx) ("jaguar" or the "company") today provided updates regarding the development program for the company's oral plant-based drug candidate canalevia™ (crofelemer delayed-release tablets) to treat chemotherapy-induced diarrhea (cid) in dogs and exercise-induced diarrhea (eid) in dogs. there currently is no fda-approved anti-secretory prescription product to manage these types of debilitating diarrhea in dogs.
JAGX Ratings Summary
JAGX Quant Ranking